One World Pharma, Inc. (OWP)

One World Pharma Company Contact:
Mimi Tekabe
One World Pharma Inc.

One World Pharma Investor Relations & Financial Media Integrity Media
Toll Free: (888) 216-3595

U.S. News & World Report Article Identifies OWP as One of 7 Marijuana Stocks to Grow in 2020

U.S. News & World Report Article Identifies OWP as One of 7 Marijuana Stocks to Grow in 2020

LAS VEGAS, NV -- December 18, 2019 -- InvestorsHub NewsWire -- One World Pharma Inc. (OTCQB:OWPC),“OWP,” a fully licensed pure-play cannabis and hemp ingredient producer in Colombia was identified by an article in U.S. News & World Report as one of ‘7 Marijuana Stocks to Grow in 2020.” The story was the featured report on U.S. News and World Report’s popular “Money” section.

U.S. News & World Report is an American media company that publishes news, opinion, consumer advice, rankings, and analysis since 1933.

An excerpt from the article:
“One World Pharma, a Las Vegas-based licensed cannabis and hemp producer which cultivates and grows them in Popayan, Colombia, is an opportunity that investors should keep an eye out for, Michael Berger says. The company recently received a quota for 2020 production of THC, a main psychoactive compound in marijuana, in Colombia and is among the first companies to be issued an amount. “The Latin American market represents an attractive opportunity due to the economics associated with the production of cannabis,” he says. “Following the issuance of government licenses, the company is positioned to record strong growth in 2020.”

“We are pleased to be recognized in an article like this in a publication that people often look to for insight as to business and the markets,” stated Brian Moore, President, One World Pharma. “Our team has worked very hard to execute the One World mission, to assemble the necessary licenses, technology and relationships to pursue the Colombian opportunity.”

“We too are very excited about what 2020 may hold for One World Pharma,” added Moore.

Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, risks related to operating in Colombia, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting One World Pharma, please refer to the Company's Current Report on 8-K/A filed with the Securities and Exchange Commission on July 12, 2019, which is available at The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Recent News:  


One World Pharma, Inc. (OWP), through its Colombian subsidiary, is a fully licensed global supplier of hemp and cannabis derived ingredients for use in manufacturing of Medical, Consumer Packaged Goods (CPGs) and Over the Counter (OTC) products. Currently, we own approximately 30 acres and have covered greenhouses built specifically to cultivate high-grade cannabis and hemp. We have entered into agreements with local farming co-operatives that include small and indigenous farmers, under which they will cultivate cannabis on up to approximately 110 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. We intend to offer our customers specific acreage that is allocated to a specific customer and with specified genetics. This will deliver consistent CBD, THC and other raw material ingredients at predetermined, consistent pricing.


Client Updates Delivered
Straight To Your Inbox

Confirm Email

Emerging Markets Report: Cannabis 2.0 & Lessons from the Dot Com Era

Press Release | 12/18/2019

ORLANDO, Fla., Dec. 18, 2019 (GLOBE NEWSWIRE) -- The year was 2001 and after a meteoric, unprecedented run, the Internet stocks, better known as the “Dot Com” bubble, were in abject decline with the general market no longer just throwing money at anything associated with the World Wide Web. But some sharper minds knew the internet itself was hardly in decline. It would continue to grow and forever change life and commerce.

What happened next was that the real Internet companies… think Google, Amazon, Apple… would harness the power of the Internet and many of their investors would be richly rewarded. The internet, you see, wasn’t going away. But the companies not positioned for its future were and eventually did.

Enter One World Pharma Inc. (OTCQB: OWPC) which is very likely one of the most unique cannabis companies you have never heard of until now. We realize the news of late is that the sector leaders are suffering losses in the market. And it is for those very reasons that One World Pharma is well-positioned. One World Pharma could be the perfect hedge against that which ails many current cannabis investments.

As with the Internet, cannabis isn’t going away. Rather it’s evolving, maturing, and sorting out the weaker hands. Growth estimates like this one from Forbes are stunning, predicting annual legal cannabis sales of $30 billion by 2025.

Early in the run on cannabis, investors and V.C. funds threw money at the few cannabis companies that were trading like it was The Dot Com Era anew. Epic rises in stock prices were common. Soon, a myriad of cannabis companies would enter the fray with a market advantage best described as first-to-market or simply because their regulatory environment would allow them to service the massive appetite for CBD and THC. Some would argue they were more early than good in hindsight.

Unlikely places like chilly Canada became pioneers for their grow-ops when warmer, more southern nations obviously made more sense. But the money flowed to the first friendly regulatory confines somehow oblivious that possible/eventual regulatory changes in warmer locales could create powerful competition with an enormous cost advantage.

Midway through 2019 the cannabis reckoning was beginning. Stocks retraced accordingly in many instances and the cannabis stocks found themselves viewed in a different, more critical light.

But in the fertile fields of a new, much more stable Colombia a few companies were already endeavoring to be a part of Cannabis 2.0, a realization of a South American nation with nearly ideal growing conditions, a friendly government intent on doing it the right way, and an experienced agrarian labor force at the ready. An opportunity to hedge your bet on the entire cannabis industry may have emerged.

So advantageous are the conditions that One World Pharma can grow cannabis for a fraction of what it costs to grow in Canada or the United States. The company has every license and permission available to grow in Colombia with its local partners. Notably, Colombia is extremely selective with whom it gives these valuable permissions. There are no lotteries or giveaways and the opportunity for companies to grow in Colombia can be counted in the low double digits.

OWP has the enormous opportunity to grow cannabis and hemp in perhaps the best location on the planet, has partnered with the local indigenous farmers to help them build a stronger economy for themselves, and aren’t focused on branding and vertical integration at the micro level. Rather, the forward looking company is focusing on cannabis as an ingredient and sold like a commodity. (More on that to come in our next editorial.)

The truth is One World’s advantages and business plan is a larger story than what we can publish in one issue of Emerging Markets Report. Over the next few weeks and months we intend to continue to explore this highly unique cannabis opportunity in greater detail. Watch for our next piece titled “For Cannabis, the Future May be Futures” and feel free to take a look at the Investor Presentation below.

For more information on One World Pharma please visit:

About The Emerging Markets Report:

The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

EMC has been paid $25,000 by One World Pharma, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. A contributor to this report holds 30,000 shares and receives $4,000 a month for a period of twelve months for investor relations services on the behalf of One World Pharma.

Recent News: